netFormulary
 Report : Medicines with links to NICE 20/09/2020 01:40:10

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 10.01.03 Formulary NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abciximab 02.09 Formulary NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Abiraterone 08.03.04.02 Formulary NICE TA259 Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Abiraterone 08.03.04.02 Formulary NICE TA387 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 10.01.03 Formulary NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Adalimumab 10.01.03 Formulary NICE TA146 Adalimumab for the treatment of adults with psoriasis
Adalimumab 10.01.03 Formulary NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 13.05.03 Formulary NICE TA146 Adalimumab for the treatment of psoriasis
Adalimumab 13.05.03 Formulary NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 01.05.03 Formulary NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 01.05.03 Formulary NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease
Adefovir Dipivoxil 05.03.03.01 Formulary NICE TA96 Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Adefovir Dipivoxil 05.03.03.01 Formulary NICE CG165 - Partially replaces TA96.
Afatinib 08.01.05 Formulary NICE TA310 Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA346 Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Alectinib 08.01.05 Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Formulary NICE TA312 Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin capsules 13.05.01 Formulary NICE TA177 Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Formulary NICE TA264 Alteplase for treating acute ischaemic stroke
Alteplase 02.10.02 Formulary NICE TA52 Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Amisulpride 04.02.01 Formulary NICE CG178 - Psychosis and schizophrenia in adults: prevention and management
Anakinra 10.01.03 Non Formulary NICE CG79 Rheumatoid arthritis in adults: management
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156
Anti-D (Rh0) Immunoglobulin 14.05 Formulary NICE TA156
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156
Apixaban 02.08.02 Formulary NICE TA275 Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apixaban 02.08.02 Formulary NICE TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA245 Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apremilast 13.05.03 Formulary NICE TA419 Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Formulary NICE TA433 Apremilast for treating active psoriatic arthritis
Aripiprazole Tablets 04.02.01 Formulary NICE TA213: Schizophrenia - aripiprazole
Aripiprazole Tablets 04.02.01 Formulary NICE TA292 - Aged 13 and older with bipolar I disorder.
Avelumab 08.01.05 Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axitinib 08.01.05 Formulary NICE TA333 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA218 Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Baricitinib 10.01.03 Formulary NICE TA466
Basiliximab 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Basiliximab 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Bee and Wasp Allergen Extracts 03.04.02 Formulary NICE TA 246 Pharmalgen for the treatment of bee and wasp venom allergy
Belimumab 10.01.03 Formulary NICE TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.05 Formulary NICE TA216 Bendamustine for CLL
Bendamustine 08.01.05 Formulary NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Benralizumab 03.04.02 Formulary NICE TA565 Benralizumab for treating severe eosinophilic asthma
Bivalirudin 02.08.01 Formulary NICE TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
Boceprevir 05.03.03.02 Formulary NICE TA253 Boceprevir for the treatment of genotype 1 chronic hepatitis C
Bortezomib 08.01.05 Formulary NICE TA311 Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib 08.01.05 Formulary NICE TA370 Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA228 Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129 Bortezomib monotherapy for relapsed multiple myeloma
Bosutinib 08.01 Formulary NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.09.03 Formulary NICE TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab 08.01.05 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab 08.01.05 Formulary NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brodalumab 13.05.03 Formulary NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis
Buprenorphine 04.10.03 Restricted Use NICE TA114
Cabazitaxel 08.01.05 Formulary NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Canagliflozin 06.01.02.03 Formulary NICE TA 315 Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canakinumab 08.02.04 Non Formulary NICE TA 302 (Nov 2013) Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal)
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil with uracil for metastatic colorectal cancer
Carmustine 08.01.01 Formulary NICE TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Celecoxib 10.01.01 Formulary NICE CG79
Celecoxib 10.01.01 Formulary NICE CG59
Ceritinib 08.01.05 Formulary NICE TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab pegol 13.05.03 Formulary NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab pegol 13.05.03 Formulary NICE TA445 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Formulary NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE 415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Cetuximab 08.01.05 Formulary NICE TA145 Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Ciclosporin 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Ciclosporin 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Ciclosporin 1 mg/mL eye drops, emulsion 11.08.01 Formulary NICE TA369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Restricted Use NICE TA117 Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Cladribine 08.01.03 Formulary NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate Sodium 05.01.07 Formulary NICE TA276 Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Collagenase Clostridium histolyticum 10.03.01 Non Formulary NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA422 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA249 Atrial fibrilation - dabigatran etexilate March 2012
Dabigatran 02.08.02 Formulary NICE TA157 Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults September 2008
Dabigatran 02.08.02 Formulary NICE TA327 - an option for treatment and for secondary prevention of recurrent DVT & PE.
Dabrafenib 08.01.05 Formulary NICE TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Daclatasvir 05.03.03.02 Restricted Use NICE TA364 Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.04 Non Formulary NICE TA441 Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating Type 1 Diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288 Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418 Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin with metformin 06.01.02.03 Formulary NICE TA288 Dapagliflozin in combination therapy for treating type 2 diabetes
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Dasatinib 08.01.05 Formulary NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Degarelix 08.03.04.02 Formulary NICE TA404 Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab 06.06.02 Formulary NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Dexamethasone 700micrograms intravitreal implant 11.04.01 Formulary NICE TA349 Dexamethasone intravitreal implant for treating diabetic macular oedema
Dexamethasone 700micrograms intravitreal implant 11.04.01 Formulary NICE TA 229. Dexamthasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dimethyl fumarate 13.05.03 Formulary NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dimethyl fumarate 08.02.04 Formulary NICE TA320 Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dipyridamole M/R Capsules 02.09 Formulary TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Formulary NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Donepezil Hydrochloride 04.11 Formulary NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin Pegylated Liposomal Infusion 08.01.02 Formulary NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Restricted Use NICE TA 197 Dronedarone for the treatment of non-permanent atrial fibrilation (Update Dec 2012)
Dupilumab 13.05.03 Formulary NICE TA534 Dupilumab for treating moderate to severe atopic dermatitis
Edoxaban 02.08.02 Formulary NICE TA355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir and grazoprevir 05.03.03.02 Formulary NICE TA413 Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Restricted Use NICE TA293 Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entecavir 05.03.03.01 Formulary NICE TA153 Entecavir for the treatment of chronic hepatitis B
Enzalutamide 08.03.03 Formulary NICE TA377 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.03.03 Formulary NICE TA316 - A possible treatment option for adults with metastatic hormone-relapsed prostate cancer, who have already had treatment with docetaxel-containing chemotherapy.
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Eptifibatide 02.09 Formulary NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Eribulin 08.01.05 Formulary NICE TA423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Ertugliflozin 06.01.02.03 Formulary NICE TA 572: Ertugliflozin as monotherapy or with metformin for treating Type 2 Diabetes
Etanercept 13.05.03 Formulary NICE TA103 Etanercept for the treatment of adults with psoriasis
Etanercept 13.05.03 Formulary NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA199
Etanercept 10.01.03 Formulary NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 10.01.03 Formulary NICE TA195
Etanercept 10.01.03 Formulary NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etelcalcetide 09.05.01.02 Formulary Technology appraisal guidance [TA448] Etelcalcetide for treating secondary hyperparathyroidism
Etodolac 10.01.01 Formulary NICE CG59
Etodolac 10.01.01 Formulary NICE CG79
Etoricoxib 10.01.01 Restricted Use NICE CG79
Etoricoxib 10.01.01 Restricted Use NICE CG59
Everolimus 08.01.05 Formulary NICE TA421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Evolocumab 02.12 Formulary NICE TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Ezetimibe 02.12 Formulary NICE TA385 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164
Fingolimod 08.02.04 Formulary NICE TA 254 Multiple Sclerosis (relapsing-remitting) fingolimod
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
fluocinolone acetonide 11.04.01 Formulary NICE TA 301 (Nov 2013) Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA 271)
Fulvestrant 08.03.04.01 Non Formulary NICE TA 239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Galantamine 04.11 Formulary NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Gefitinib 08.01.05 Formulary NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gefitinib 08.01.05 Formulary NICE TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Glatiramer Acetate 08.02.04 Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Golimumab 10.01.03 Formulary NICE TA220 Golimumab for the treatment of psoriatic arthritis
Golimumab 10.01.03 Formulary NICE TA225 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Golimumab 10.01.03 Formulary NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Guselkumab 13.05.03 Formulary NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis
Ibrutinib 08.01.05 Formulary NICE TA429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Idelalisib 08.01.05 Formulary NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia
Imatinib 08.01.05 Formulary NICE TA209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA70 Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Infliximab 01.05.03 Formulary NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 01.05.03 Formulary NICE TA163 Infliximab for acute exacerbations of ulcerative colitis
Infliximab 10.01.03 Formulary NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 10.01.03 Formulary NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA134 Infliximab for the treatment of adults with psoriasis
Infliximab 10.01.03 Formulary NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 10.01.03 Formulary NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Infliximab infusion 13.05.03 Formulary NICE TA134 Infliximab for the treatment of adults with psoriasis
Infliximab infusion 13.05.03 Formulary NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Interferon Alfa 08.02.04 Formulary NICE TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Interferon Alfa 08.02.04 Formulary NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Interferon Alfa 08.02.04 Formulary NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Interferon Alfa 08.02.04 Formulary NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Interferon Alfa 08.02.04 Formulary NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Interferon Alfa 08.02.04 Formulary NICE TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Interferon Alfa 08.02.04 Formulary NICE TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Interferon Beta 08.02.04 Formulary NICE TA32
Interferon Beta 08.02.04 Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta 08.02.04 Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA268 Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Irinotecan Hydrochloride 08.01.05 Non Formulary NICE CG131
Ivabradine 02.06.03 Formulary NICE TA267 - Ivabradine for Treating Chronic Heart Failure
Ixazomib 08.01.05 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 13.05.03 Formulary NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab 13.05.03 Formulary NICE TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lapatinib 08.01.05 Non Formulary NICE TA257
Ledipasvir and sofosbuvir 05.03.03.02 Formulary NICE TA363 Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA171 Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenalidomide 08.02.04 Formulary NICE TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenvatinib 08.01.05 Formulary NICE TA551:Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Liposomal cytarabine–daunorubicin 08.01.02 Formulary NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Lubiprostone 01.06.07 Non Formulary NICE TA318 Lubiprostone for treating chronic idiopathic constipation
Mannitol dry powder for inhalation 03.07 Formulary NICE TA266 Mannitol dry powder for inhalation for treating cystic fibrosis
Meloxicam 10.01.01 Formulary NICE CG59
Meloxicam 10.01.01 Formulary NICE CG79
Memantine Hydrochloride 04.11 Formulary NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Mepolizumab 03.04.02 Formulary NICE TA431 Mepolizumab for treating severe refractory eosinophilic asthma
Methadone Hydrochloride preparations 04.10.03 Restricted Use NICE TA114
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis in adults; management
Mifamurtide 08.02.04 Formulary NICE TA235 Mifamurtide for the treatment of osteosarcoma
Mirabegron 07.04.02 Formulary NICE TA 290 Mirabegron Mirabegron for treating symptoms of overactive bladder
Mycophenolate Mofetil 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Mycophenolate Mofetil 08.02.01 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Naftidrofuryl Oxalate 02.06.04 Formulary NICE TA223 Treatment of intermittent claudication in people with peripheral arterial disease
Nalmefene 04.10.01 Restricted Use NICE TA 325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06 Formulary NICE TA345 Naloxegol for treating opioid‑induced constipation
Naltrexone Hydrochloride 04.10.03 Restricted Use NICE TA115
Natalizumab 08.02.04 Formulary NICE TA127
Nilotinib 08.01.05 Formulary NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nintedanib 03.11 Formulary NICE TA379 Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA347 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.01.05 Formulary NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.01.05 Formulary NICE TA417 Nivolumab for previously treated advanced renal cell carcinoma
Obeticholic acid 01.09.01 Formulary NICE TA443 Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA343 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Ocriplasmin 11.08.02 Formulary NICE TA 297:Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.01.05 Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olanzapine Tablets 04.02.01 Formulary NICE CG178 - Psychosis and schizophrenia in adults: prevention and management
Olanzapine Tablets 04.02.01 Formulary NICE CG185 - Bipolar disorder: assessment and management
Omalizumab 03.04.02 Formulary NICE TA339 Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA278 Omalizumab for treating severe persistent allergic asthma (updates and replaces 133 and 201)
Ombitasvir, Paritaprevir and Ritonavir 05.03.03.02 Formulary NICE TA365 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Formulary NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza
Oseltamivir 05.03.04 Formulary NICE TA158 Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Osimertinib 08.01.05 Formulary NICE TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100:Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Paclitaxel 08.01.05 Formulary NICE TA55:Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Palbociclib 08.01.05 Formulary NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Palbociclib 08.01.05 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Formulary NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patiromer calcium 09.02.01.01 Formulary NICE TA 623: Patiromer for treating hyperkalaemia
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
Pegaspargase 17 Formulary NICE TA408 Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA 300 (Nov 13) Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA96
Peginterferon Alfa 08.02.04 Formulary NICE CG165 - Partially replaces TA96
Peginterferon Alfa 08.02.04 Formulary NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA300 (Nov 13) Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA300 (Nov 2013) Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE CG165 - Partially replaces TA96
Peginterferon Alfa 08.02.04 Formulary NICE TA96
Peginterferon Beta 08.02.04 Formulary NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pembrolizumab 08.01.05 Formulary NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA124 - Lung cancer (non small-cell)- prior chemotherapy.
Pemetrexed 08.01.03 Formulary NICE TA402 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pertuzumab 08.01.05 Formulary NICE TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus cream 13.05.03 Formulary NICE TA82 Tacrolimus and pimecrolimus for atopic eczema
Pirfenidone 10.01.05 Formulary NICE TA282 Pirfenidone for treating idiopathic pulmonary fibrosis
Pirfenidone 03.11 Formulary NICE TA504:Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA427 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Prasugrel 02.09 Formulary NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Prucalopride 01.06 Formulary NICE TA211 Prucalopride for the treatment of chronic constipation in women
Quetiapine 04.02.01 Formulary NICE CG178 - Psychosis and schizophrenia in adults: prevention and management
Quetiapine Modified Release 04.02.01 Formulary NICE CG178 - Psychosis and schizophrenia in adults: prevention and management
Radium-223 dichloride 08.03.04.02 Formulary NICE TA412 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene hydrochloride 06.04.01.01 Formulary NICE TA161
Raloxifene hydrochloride 06.04.01.01 Formulary NICE TA160
Ranibizumab 11.08.02 Formulary NICE TA274 (April 2013) Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237)
Ranibizumab 11.08.02 Formulary NICE TA281 (May 2013) Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 11.08.02 Formulary NICE TA298 (Nov 13) Choroidal neovascularisation (pathological myopia) - ranibizumab
Ranibizumab 11.08.02 Formulary NICE TA 155 (Aug 2008) Ranibizumab & pegaptanib for the treatment of wet AMD
Regorafenib 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Formulary NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Formulary NICE TA479 Reslizumab for treating severe eosinophilic asthma
Reteplase 02.10.02 Formulary NICE TA52 Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Retigabine 04.08.01 Formulary NICE TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy
Ribavirin 05.03.05 Formulary NICE TA106
Ribavirin 05.03.05 Formulary NICE TA200
Ribavirin 05.03.05 Formulary NICE TA75
Ribavirin 05.03.05 Formulary NICE TA300 (Nov 2013) Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribociclib 08.01.05 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Formulary NICE TA 337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20
Risankizumab 13.05.03 Formulary NICE TA596 Risankizumab for treating moderate to severe plaque psoriasis
Risperidone 04.02.01 Formulary NICE CG178 - Psychosis and schizophrenia in adults: prevention and management
Risperidone 04.02.02 Formulary NICE CG82 - Psychosis and schizophrenia: management
Rituximab 08.02.03 Formulary NICE TA243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma: (review of NICE technology appraisal guidance 110)
Rituximab 08.02.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 08.02.03 Formulary NICE TA137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkins lymphoma
Rituximab 08.02.03 Formulary NICE TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab 10.01.03 Formulary NICE TA 308 Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 10.01.03 Formulary NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA170 Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults April 2009
Rivaroxaban 02.08.02 Formulary NICE TA 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivaroxaban 02.08.02 Formulary NICE TA256 Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrilation. May 2012
Rivaroxaban 02.08.02 Formulary NICE TA287 Pulmonary embolism and recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivastigmine 04.11 Formulary NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Roflumilast 03.03.03 Formulary NICE TA461 Roflumilast for treating Chronic Obstructive Pulmonary Disease
Romiplostim 09.01.04 Restricted Use NICE TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
Ruxolitinib 08.01.05 Formulary NICE TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril/valsartan 02.05 Formulary NICE TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 10.01.03 Formulary NICE TA485
Secukinumab 13.05.03 Formulary NICE TA445 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Formulary NICE TA350 Secukinumab for treating moderate to severe plaque psoriasis
Sertindole 04.02.01 Formulary NICE CG178
Simeprevir 05.03.03.02 Formulary NICE TA331Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sirolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Sirolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Sodium zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 05.03.03.02 Formulary NICE TA330 Sofosbuvir for treating chronic hepatitis C
Sofosbuvir and Velpatasvir 05.03.03.02 Formulary NICE TA430 Sofosbuvir–velpatasvir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA188
Somatropin 06.05.01 Formulary NICE TA64
Streptokinase 02.10.02 Formulary NICE TA52 Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Strontium Ranelate 06.06.02 Non Formulary NICE TA161
Strontium Ranelate 06.06.02 Non Formulary NICE TA 160
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Tacrolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus ointment 13.05.03 Formulary NICE TA82 Tacrolimus and pimecrolimus for atopic eczema
Tadalafil 2.5mg, 5mg tablets 07.04.05 Non Formulary NICE TA 273: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)
Talimogene laherparepvec 17 Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tamoxifen 08.03.04.01 Formulary NICE CG164
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61
Telaprevir 05.03.03.02 Formulary NICE TA252 Telaprevir for the treatment of genotype 1 chronic hepatitis C
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Tenecteplase 02.10.02 Formulary NICE TA52 Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Tenofovir Disproxil 05.03.01 Formulary NICE TA173 Tenofovir disoproxil for the treatment of chronic hepatitis B
Teriflunomide 08.02.04 Formulary NICE TA303 Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide 06.06.01 Formulary NICE TA161
Thalidomide 08.02.04 Formulary NICE TA228 Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Formulary NICE TA236 Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420 Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Formulary NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis
Tirofiban 02.09 Formulary NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Tivozanib 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin 05.01.04 Formulary NICE TA276 Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tocilizumab 10.01.03 Formulary NICE TA238 Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA247 Tocilizumab for the treatment of rheumatoid arthritis (updates and replaces ta198)
Tocilizumab 10.01.03 Formulary NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Formulary NICE TA185 Trabectedin for the treatment of advanced soft tissue sarcoma
Trametinib 08.01.05 Formulary NICE TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Formulary Link to CDF secure application site
Trastuzumab 08.01.05 Formulary NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trastuzumab 08.01.05 Formulary NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Trifluridine and tipiracil 17 Formulary NICE TA405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab infusion / subcutaneous 13.05.03 Formulary NICE TA180 Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab infusion / subcutaneous 13.05.03 Formulary NICE TA340 Ustekinumab for treating active psoriatic arthritis
Vedolizumab 01.05.03 Formulary NICE TA352 Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342 Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269 Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary Link to CDF secure application site
Verteporfin 11.08.02 Formulary NICE TA68
Vismodegib 08.01 Non Formulary Negative NICE TA489 for basal cell carcinoma
Vortioxetine 04.03.04 Formulary NICE TA367 Vortioxetine for treating major depressive episodes
Zaleplon 04.01.01 Formulary NICE TA77 - Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Zanamivir 05.03.04 Formulary NICE TA158 Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zanamivir 05.03.04 Formulary NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zolpidem Tartrate Tablets 04.01.01 Formulary NICE TA77 - Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Zopiclone Tablets 04.01.01 Formulary NICE TA77 - Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Zotepine 04.02.01 Non Formulary NICE CG82
Herefordshire & Worcestershire